About Anacor Pharmaceuticals
Anacor Pharmaceuticals is a Healthcare company based in Palo Alto (United States) founded in 2002, and was acquired by Pfizer in May 2016. Anacor Pharmaceuticals has raised $90 million across 9 funding rounds from investors including Pfizer, Hercules Capital and Gates Foundation. The company has 110 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified. Its legal entity is ANACOR PHARMACEUTICALS, INC. Its competitors include Vir Biotechnology, Vaxcyte and Cidara Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of small-molecule therapeutics for the treatment of infectious and autoimmune diseases. The companys products include AN2690, a topical antifungal for the treatment of onychomycosis, AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis, and GSK 2251052, or GSK 052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
- Headquarters Palo Alto, United States
- Employees 110
- Stage Acquired
- SectorsHealthcare
- Website anacor.com
- Social LinkedIn
- Acquired by Pfizer (May 2016)
- Legal Name Anacor Pharmaceuticals, Inc.
Funding Insights of Anacor Pharmaceuticals
Anacor Pharmaceuticals has successfully raised a total of $90M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90M
- Total Rounds 9
- Last Round Post-IPO — $250M
- First Round $25M
(May 2005)
- Investors Count 9
All 9 funding rounds of Anacor Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | $250M | Post-IPO | – | – | – |
| Jun 2013 | $45M | Debt – Venture | – | – | |
| Apr 2013 | $5M | Post-IPO | – | – | |
| Apr 2013 | $17.7M | Grant | – | – | |
| Dec 2010 | $10M | Post-IPO | – | – | – |
| Nov 2010 | $1.5M | Grant | – | – | |
| Jul 2010 | $15M | Series E | – | GSK | – |
| Jan 2009 | $50M | Series E | – | – | |
| May 2005 | $25M | Series C | – | – |
10 investors in total: 10 institutional.
Investors in Anacor Pharmaceuticals
Anacor Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Hercules Capital and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
| carecapital.com | ||||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
Venture capital firm investing in life sciences companies | redabbey.com | Baltimore, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
The U.S. Department of the Treasury is tasked with formulating and implementing fiscal policy for the United States government. | 1789 | treasury.gov | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Anacor Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Anacor Pharmaceuticals
5 dated milestones of Anacor Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Anacor Pharmaceuticals is founded.
- Funding First funding round of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $250.0M.
- Exit Acquired by Pfizer.
Competitors of Anacor Pharmaceuticals
Anacor Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Vir Biotechnology, Vaxcyte and Cidara Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. |
Detailed competitors of Anacor Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Anacor Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anacor Pharmaceuticals
Complete news archive for Anacor Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anacor Pharmaceuticals
Anacor Pharmaceuticals was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Anacor Pharmaceuticals is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Anacor Pharmaceuticals is a funded company, having raised a total of $90M across 9 funding rounds to date. The company's 1st funding round was a Series C of $25M, raised on May 2005.
Anacor Pharmaceuticals has 110 employees.
Developer of small-molecule therapeutics for the treatment of infectious and autoimmune diseases. The companys products include AN2690, a topical antifungal for the treatment of onychomycosis, AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis, and GSK 2251052, or GSK 052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
Anacor Pharmaceuticals's top competitors include Vaxcyte, Vir Biotechnology and Cidara Therapeutics.
Anacor Pharmaceuticals has 10 investors. Key investors include Pfizer, Hercules Capital, Gates Foundation, GSK, and U.S. Department of the Treasury.
Anacor Pharmaceuticals operates through Anacor Pharmaceuticals, Inc..
Yes. Anacor Pharmaceuticals was acquired by Pfizer in May 2016.